Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 05, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR), specifically detailing interim long-term incentive (LTI) awards granted to Dan Troy, Senior Vice President and General Counsel, who joined the company in September 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and specific grant details rather than consolidated financial performance.
Material Changes
The primary material change reported is the grant of new equity-based awards to a senior executive on November 04, 2008. These awards are subject to performance conditions tied to Total Shareholder Return (TSR) and Earnings Per Share (EPS) growth over a three-year period commencing January 1, 2008.
Guidance, Outlook, and Management Commentary
- Performance Share Plan: Awards vest based on GSK's TSR relative to 14 comparator companies (including Pfizer, Merck, and Johnson & Johnson) over the 2008-2010 period. No awards vest if performance ranks below the median; 100% vests if ranked first or second.
- Share Option Plan: Vesting depends on EPS growth exceeding the Retail Price Index (RPI) by 3% per annum. 50% of options vest at the 3% hurdle, increasing to 100% at 6% or more.
- Grant Details: Options were granted with an exercise price of US$40.19. The expected vesting date for the Performance Share Plan is February 2011, and for the Share Option Plan, November 4, 2011.
- Risks and Contingencies: The filing notes that awards or options will lapse if performance conditions are not met. The number of ADSs potentially vesting varies significantly based on performance thresholds.
Important Facts for Investor Verification
- Verify the specific number of ADSs granted to Dan Troy under both the Performance Share Plan and Share Option Plan.
- Confirm the exercise price of US$40.19 for the share options granted on November 4, 2008.
- Review the list of 14 comparator companies used for the TSR performance metric.
- Monitor the company's EPS growth relative to the RPI to assess the likelihood of option vesting.
- Note that the filing does not contain updated financial statements or guidance for the fiscal year.